Unlearn.AI Closes $12M Series A to Advance the Use of Digital Twins in Clinical Trials

SAN FRANCISCO, Calif. April 20, 2020 Unlearn.AI, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that it has closed a $12 million Series A financing. The financing round was led by 8VC with participation from all the company's existing investors including DCVC, DCVC Bio and Mubadala Capital Ventures. Through its investment, 8VC Principal Francisco Gimenez, Ph.D., has joined the Unlearn Board of Directors.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

CTAD 2020: Unlearn will present abstracts to demonstrate how Digital Twins enable smaller, more efficient trials

Blog

Announcing The Unlearn Opportunities Internship Program

Podcasts

UCSF Rosenman Institute - The Health Technology Podcast #59: Digital Twins for Clinical Trials

Charles Fisher: Digital Twins for Clinical Trials
Creating Opportunities for Students of Data Science and Business from Underrepresented Groups in STEM
Unlearn will present data from two separate abstracts demonstrating how Digital Twins can power novel trial designs and accelerate timelines.